Metabolic-inflammatory status as predictor of clinical outcome at 1-year follow-up in patients with first episode psychosis.
Adult
Antipsychotic Agents
/ therapeutic use
Biomarkers
Blood Glucose
/ analysis
Body Mass Index
C-Reactive Protein
/ analysis
Case-Control Studies
Cholesterol
Female
Follow-Up Studies
Glycated Hemoglobin
/ analysis
Humans
Inflammation
/ metabolism
Insulin Resistance
/ physiology
Longitudinal Studies
Male
Prognosis
Psychiatric Status Rating Scales
Psychotic Disorders
/ metabolism
Treatment Outcome
Triglycerides
BMI
Clinical outcome
First episode psychosis
Inflammation
Metabolism
Predictor
Journal
Psychoneuroendocrinology
ISSN: 1873-3360
Titre abrégé: Psychoneuroendocrinology
Pays: England
ID NLM: 7612148
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
21
04
2018
revised:
31
07
2018
accepted:
07
09
2018
pubmed:
23
9
2018
medline:
1
6
2019
entrez:
23
9
2018
Statut:
ppublish
Résumé
Metabolic abnormalities and peripheral inflammation have been increasingly reported in patients at the onset of psychosis and associated with important physical health disorders and increased mortality. However, the impact of an abnormal metabolic-inflammatory status on the psychiatric outcome of these patients has not yet been investigated. The aims of this study were 1) to explore whether, in a sample of patients at their first episode of psychosis (FEP), an overall metabolic-inflammatory status may be measured, by combining metabolic and inflammatory variables in metabolic-inflammatory factors; 2) to explore the association between these factors and clinical outcome at 1-year follow-up (FU), in terms of symptoms severity and treatment response. In this longitudinal study we recruited 42 FEP patients and 46 healthy controls (HC) matched with patients for age, gender and ethnicity. At baseline (T1) we measured high sensitivity C-reactive protein (hsCRP) as biomarker of inflammation, and body mass index (BMI), lipid profile and gluco-metabolic parameters (glycated hemoglobin (HbA1c) and fasting glucose) as metabolic variables. A principal component analysis (PCA) was then used to reduce the dimensionality of the dataset accounting for both inflammation and metabolic status. In FEP patients, we assessed symptoms severity at T1 and at 1-year FU (T2) as well as treatment response to antipsychotics at T2. at T1, FEP showed higher HbA1c (p = 0.034), triglycerides (TG) (p = 0.045) and BMI (p = 0.026) than HC. PCA identified 3 factors: factor 1 accounting for hsCRP, TG and BMI, factor 2 accounting for LDL and cholesterol, and factor 3 accounting for fasting glucose and HbA1c. Factor 1 was associated with T1 negative symptoms severity (p = 0.021) and predicted T2 positive (p = 0.004) and overall symptoms severity (0.001), as well as general psychopathology (p < 0.001) and T2 treatment response (p = 0.007). In this sample of FEP patients, inflammation and metabolism, closely correlated at the onset of psychosis, proved to play a key role as predictors of the clinical course of psychosis when combined in a single factor. These findings offer an important potential target for early screening and interventions.
Sections du résumé
BACKGROUND
Metabolic abnormalities and peripheral inflammation have been increasingly reported in patients at the onset of psychosis and associated with important physical health disorders and increased mortality. However, the impact of an abnormal metabolic-inflammatory status on the psychiatric outcome of these patients has not yet been investigated.
OBJECTIVES
The aims of this study were 1) to explore whether, in a sample of patients at their first episode of psychosis (FEP), an overall metabolic-inflammatory status may be measured, by combining metabolic and inflammatory variables in metabolic-inflammatory factors; 2) to explore the association between these factors and clinical outcome at 1-year follow-up (FU), in terms of symptoms severity and treatment response.
METHODS
In this longitudinal study we recruited 42 FEP patients and 46 healthy controls (HC) matched with patients for age, gender and ethnicity. At baseline (T1) we measured high sensitivity C-reactive protein (hsCRP) as biomarker of inflammation, and body mass index (BMI), lipid profile and gluco-metabolic parameters (glycated hemoglobin (HbA1c) and fasting glucose) as metabolic variables. A principal component analysis (PCA) was then used to reduce the dimensionality of the dataset accounting for both inflammation and metabolic status. In FEP patients, we assessed symptoms severity at T1 and at 1-year FU (T2) as well as treatment response to antipsychotics at T2.
RESULTS
at T1, FEP showed higher HbA1c (p = 0.034), triglycerides (TG) (p = 0.045) and BMI (p = 0.026) than HC. PCA identified 3 factors: factor 1 accounting for hsCRP, TG and BMI, factor 2 accounting for LDL and cholesterol, and factor 3 accounting for fasting glucose and HbA1c. Factor 1 was associated with T1 negative symptoms severity (p = 0.021) and predicted T2 positive (p = 0.004) and overall symptoms severity (0.001), as well as general psychopathology (p < 0.001) and T2 treatment response (p = 0.007).
CONCLUSION
In this sample of FEP patients, inflammation and metabolism, closely correlated at the onset of psychosis, proved to play a key role as predictors of the clinical course of psychosis when combined in a single factor. These findings offer an important potential target for early screening and interventions.
Identifiants
pubmed: 30243054
pii: S0306-4530(18)30398-6
doi: 10.1016/j.psyneuen.2018.09.005
pii:
doi:
Substances chimiques
Antipsychotic Agents
0
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
Triglycerides
0
hemoglobin A1c protein, human
0
C-Reactive Protein
9007-41-4
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-153Subventions
Organisme : Medical Research Council
ID : MR/J002739/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008436/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N029488/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G108/603
Pays : United Kingdom
Organisme : MRF
ID : MRF_C0439
Pays : United Kingdom
Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.